Newsfeeds - Spark Newswire

2 minute read

Novel Approach To Treating Advanced Liver Cancer With Namodenoson Published In Leading Scientific Journal: 12-Month Survival Of 44% For Namodenoson Vs. 18% For Placebo

February 14, 9:16 AM

Namodenoson is being evaluated in a pivotal Phase III study Namodenoson is approved for compassionate use in the treatment of liver cancer in Israel and Romania Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

3 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

February 10, 2:22 PM

During Friday, 48 stocks hit new 52-week lows.

ABEV

1 minute read

Can-Fite BioPharma Files Prospectus Related To Resale Of Up To An Aggregate Of 955.909M Ordinary Shares, Represented By 3.1M ADRs

By Michael Horton

January 31, 6:53 PM

-SEC Filing

CANF

3 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

January 4, 1:11 PM

On Wednesday, 35 companies reached new 52-week lows.

ARQQ

1 minute read

Can-Fite’s Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer

By Vandana Singh

December 28, 11:21 AM

Can-Fite BioPharma Ltd (NASDAQ:CANF) provided an update on its clinical program for Namodenoson for hepatocellular carcinoma (HCC). At two upcoming conferences,…

CANF

1 minute read

Can-Fite BioPharma To Present Liver Cancer Data At Upcoming Conferences

By Bill Haddad

December 28, 8:05 AM

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today provided an update on

CANF

25 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

October 21, 1:26 PM

On Friday morning, 446 companies hit new 52-week lows.

ABG

1 minute read

Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology

By Benzinga Newsdesk

September 12, 7:02 AM

Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis

CANF

2 minute read

Can-Fite Announces Piclidenoson Is Set To Enter Clinical Trial For Treatment Of Osteoarthritis In Dogs Efficacy Trial To Commence And Financially Covered By Vetbiolix

By Bill Haddad

August 17, 7:27 AM

Safety study successfully completed; efficacy trial to commence and financially covered by Vetbiolix Canine osteoarthritis market is projected to reach $3 billion by 2028 PETACH TIKVA, Israel--(BUSINESS WIRE)--

CANF

6 minute read

Boeing, PriceSmart And 80 Biggest Movers From Yesterday

By Lisa Levin

July 13, 4:59 AM

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

AAL